Stock Detail
GERON CORPORATION
Biotechnology
GERN @ Yahoo Finance | GERN Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $1.62 | $1.77 | $-0.13 | -7.43% | 0.00 | $1.75 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $1.68 | $1.59 | 3.33M | 212.99M | 1.51M | -1.45 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 1.84 | 1.73 | 1.66 | 1.55 | 1.48 |
Stock Profile
Geron Corporation, a biopharmaceutical company, engages in the development and commercialization of therapeutic and diagnostic products for cancer based on its telomerase technology, and cell-based therapeutics using its human embryonic stem cell (HESC) technology. The company develops anticancer therapies based on telomerase inhibitors, telomerase therapeutic vaccines, and, through its licensees, telomerase-based oncolytic (cancer-killing) viruses. It uses HESCs for the manufacture of replacement cells and tissues. It intends to use HESC technology to enable the development of transplantation therapies, facilitate pharmaceutical research and development practices, and for research in human developmental biology. Geron Corporation's nuclear transfer technology is a method for generating whole animals from genetic material derived solely from the nucleus of a single cell obtained from an individual animal. The company was incorporated in 1990 and is headquartered in Menlo Park, California.